secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001558370-24-015608
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix Q3 net income $3.2M, revenue up 75%; PRX-115 Phase I positive
----------------------------------------------------------------------

- Revenue from goods $17.8M (+75% YoY); net income $3.2M vs loss $1.9M in Q3 2023; EPS $0.04 basic.
- PRX-115 Phase I completed all eight cohorts; single dose lowered uric acid below 6.0 mg/dL for up to 12 weeks at highest doses.
- PRX-115 well-tolerated: 25% of treated subjects reported mild-to-moderate AEs; one resolved anaphylactic reaction.
- Cash $27.4M at Sept 30; repaid 7.5% senior secured convertible notes due Sept 2024 from available cash.
- Planning phase II trial of PRX-115 in gout patients, initiation expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024015608/0001558370-24-015608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837024015608/plx-20241114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer